Journal
JOURNAL OF CLINICAL MEDICINE
Volume 11, Issue 7, Pages -Publisher
MDPI
DOI: 10.3390/jcm11071891
Keywords
peritoneal carcinomatosis; gastrointestinal cancer; cytoreductive surgery; HIPEC; immunotherapy; PRODIGE; peritoneal mesothelioma
Categories
Ask authors/readers for more resources
Malignant peritoneal mesothelioma is a rare malignancy that is diagnosed through cross sectional imaging and tissue biopsy. Surgical cytoreduction and chemotherapy are the preferred treatments, providing prolonged benefits to many patients.
Malignant peritoneal mesothelioma is a rare malignancy arising from the serosa of the peritoneal cavity. It is diagnosed based on suspicious findings on cross sectional imaging and a tissue biopsy showing confirmatory histologic and immunohistochemical features. The disease is hallmarked by its propensity to progress mainly in the peritoneal cavity. In selected patients, surgical cytoreduction and hyperthermic intra-operative peritoneal chemotherapy has become the initial preferred treatment and is associated with provide prolonged in many patients. Systemic chemotherapy using a couplet of cisplatin or gemcitabine with pemetrexed has modest response rates and duration of response. Expression of PD-L1 has been demonstrated in peritoneal mesothelioma tumors and there has been significant interest in the use of check point blockade targeted against PD-L1 in this clinical setting. Future clinical research using a combination of check point blockade with surgical cytoreduction is a high clinical priority.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available